A randomized, double-blind Phase 3 study of S-474474 in patients with essential hypertension, - Evaluation in non-responder to irbesartan
Phase 3
- Conditions
- Hypertension
- Registration Number
- JPRN-jRCT2080221107
- Lead Sponsor
- SHIONOGI & CO., LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with essential hypertension who meet the following criteria:
Seated trough systolic blood pressure is not less than140 mmHg, lower than180 mmHg,and seated trough diastolic blood pressure is not less than 90 mmHg, lower than 110 mmHg. etc.
Exclusion Criteria
Patients with renal, hepatic or heart disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in trough seated diastolic blood pressure
- Secondary Outcome Measures
Name Time Method Adverse events and adverse drug reactions, etc
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the molecular mechanism of S-474474 in targeting essential hypertension pathways?
How does S-474474 compare to irbesartan in managing resistant hypertension patient outcomes?
Are there specific biomarkers that predict response to S-474474 in non-irbesartan responders?
What adverse events are associated with S-474474 and how are they managed in clinical practice?
What are the potential combination therapies involving S-474474 and other antihypertensive drug classes?